Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)†

Article English OPEN
Gerber, B. ; Loibl, S. ; Eidtmann, H. ; Rezai, M. ; Fasching, P. A. ; Tesch, H. ; Eggemann, H. ; Schrader, I. ; Kittel, K. ; Hanusch, C. ; Kreienberg, R. ; Solbach, C. ; Jackisch, C. ; Kunz, G. ; Blohmer, J. U. ; Huober, J. ; Hauschild, M. ; Nekljudova, V. ; Untch, M. ; von Minckwitz, G. (2017)

Background We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients with triple-negative breast cancer (TNBC). Patient... View more
Share - Bookmark